No. 18-817
Hikma Pharmaceuticals USA Inc., et al. v. Vanda Pharmaceuticals Inc.
Tags: generic-drugs inventive-concept medical-patent medical-treatment method-of-treatment natural-law patent-eligibility routine-and-conventional section-101
Latest Conference:
2020-01-10
(distributed 2 times)
Question Presented (from Petition)
Whether patents that claim a method of medically treating a patient automatically satisfy Section 101 of the Patent Act, even if they apply a natural law using only routine and conventional steps.
Question Presented (AI Summary)
Whether patents that claim a method of medically treating a patient automatically satisfy Section 101 of the Patent Act, even if they apply a natural law using only routine and conventional steps
Docket Entries
2020-01-13
Petition DENIED.
2019-12-26
Letter of December 26, 2019 from counsel for petitioner received. (Distributed)
2019-12-23
Supplemental brief of respondent Vanda Pharmaceuticals USA, Inc. filed. (Distributed)
2019-12-23
DISTRIBUTED for Conference of 1/10/2020.
2019-12-20
Supplemental brief of petitioners Hikma Pharmaceuticals USA Inc., et al. filed.
2019-12-06
Brief amicus curiae of United States filed.
2019-05-22
Amendment to Rule 29.6 Corporate Disclosure Statement filed with respect to brief in opposition of respondent Vanda Pharmaceuticals Inc.
2019-03-18
The Solicitor General is invited to file a brief in this case expressing the views of the United States.
2019-03-15
Letter of Hikma Pharmaceuticals USA Inc., et al. received.
2019-02-27
DISTRIBUTED for Conference of 3/15/2019.
2019-02-26
Reply of petitioners Hikma Pharmaceuticals USA Inc., et al. filed.
2019-02-12
Brief of respondent Vanda Pharmaceuticals USA, Inc. in opposition filed.
2019-01-28
Brief amici curiae of The Association for Accessible Medicines and Certain Individual Companies filed.
2019-01-28
Brief amici curiae of Intellectual Property and Innovation Professors, Engine Advocacy, et al. filed.
2019-01-23
Motion to extend the time to file a response is granted and the time is extended to and including February 12, 2019.
2019-01-22
Motion to extend the time to file a response from January 28, 2019 to February 12, 2019, submitted to The Clerk.
2018-12-27
Petition for a writ of certiorari filed. (Response due January 28, 2019)
2018-10-31
Application (18A461) granted by The Chief Justice extending the time to file until December 27, 2018.
2018-10-26
Application (18A461) to extend the time to file a petition for a writ of certiorari from November 12, 2018 to December 27, 2018, submitted to The Chief Justice.
Attorneys
Hikma Pharmaceuticals USA Inc., et al.
Charles Bennett Klein — Winston & Strawn LLP, Petitioner
Intellectual Property and Innovation Professors, Engine Advocacy, and The R Street Institute
THE ASSOCIATION FOR ACCESSIBLE MEDICINES AND CERTAIN INDIVIDUAL COMPANIES
United States
Noel J. Francisco — Solicitor General, Amicus
Vanda Pharmaceuticals USA, Inc.